Neuropace Inc (NPCE) Stock Price, Quote & News

Company Profile

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for...

Industry: Medical Devices

Sector: Healthcare

Phone: 650 237 2700

Website: www.neuropace.com

Address:

455 North Bernardo Avenue, Mountain View, United States

focafoca99 May. 29 at 12:43 PM

$NPCE provides details on its participation at the ASSFN meeting, showcasing responsive neuromodulation and new RNS System data.

0 · Reply

Stock_Catcher May. 29 at 12:02 PM

$NPCE NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

0 · Reply

SuperGreenToday May. 19 at 1:16 PM

$NPCE Share Price: $16.01 Contract Selected: Nov 20, 2026 $15 Calls Buy Zone: $3.44 – $4.25 Target Zone: $5.53 – $6.76 Potential Upside: 52% ROI Time to Expiration: 184 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

MarketBeat May. 13 at 1:10 AM

https://marketbeat.com/a/8651185/ $NPCE NeuroPace Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 12 at 10:16 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-neuropace-inc-stock/ $NPCE NeuroPace Earnings Transcript

0 · Reply

StocktwitsEarnings May. 12 at 8:12 PM

$NPCE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.20 up 4.76% YoY • Reported revenue of $22.07M down -2.02% YoY • NeuroPace raised full year 2026 revenue guidance to $99M to $101M and increased Adjusted EBITDA guidance to a loss between -$8.5M and -$9.5M, reflecting underlying RNS growth.

0 · Reply

focafoca99 Apr. 11 at 9:03 PM

$NPCE management will present at the Needham Virtual Healthcare Conference on April 14.

0 · Reply

OfficialStocktwitsUser Mar. 23 at 3:54 PM

$NPCE RSI: 43.25, MACD: -0.4525 Vol: 0.53, MA20: 14.03, MA50: 15.08 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StocktwitsEarnings Mar. 3 at 10:05 PM

$NPCE Q4 '25 Earnings Results & Recap • Reported GAAP EPS of -$0.08 up 55.56% YoY • Reported revenue of $26.59M up 23.86% YoY • NeuroPace expects its cash, cash equivalents, and short-term investments will fund operations for at least 12 months from December 31, 2025, and its trailing 12-month RNS System revenue of $81.7 million exceeded the $71.0 million minimum covenant.

0 · Reply

d_risk Mar. 3 at 10:03 PM

$NPCE - Neuropace Inc - 10K - Updated Risk Factors NPCE’s risk profile now flags QMSR manufacturing compliance, weaker NAUTILUS topline efficacy, heightened exposure to shifting tariffs and trade tensions, major U.S. health policy and Medicaid cuts (OBBBA, Great Healthcare Plan), stricter global data/AI rules, new DOJ data-transfer limits, loss of the DIXI distribution upside, tighter MidCap debt covenants, and vulnerability to FDA/SEC shutdowns. #MedicalDevices #RegulatoryCompliance #TradeTariffs #HealthcarePolicy #DataPrivacy 🟢 Added 🟠 Removed https://d-risk.ai/NPCE/10-K/2026-03-03

0 · Reply

NeuroPace announces FDA approval of ECoG Assistant

May 29, 2026, 8:05 AM EDT - 9 hours ago

NeuroPace to Highlight Expanding Role of Responsive Neuromodulation at the 2026 American Society for Stereotactic and Functional Neurosurgery (ASSFN) Meeting

May 29, 2026, 8:00 AM EDT - 9 hours ago

NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

2026-05-15T18:24:06.000Z - 14 days ago

NeuroPace price target raised to $20 from $19 at H.C. Wainwright

May 12, 2026, 9:09 PM EDT - 16 days ago

NeuroPace Q1 Earnings Call Highlights

2026-05-12T21:03:25.000Z - 17 days ago

NeuroPace reports Q1 EPS (20c), consensus (23c)

2026-05-12T21:02:09.000Z - 17 days ago

NeuroPace raises FY26 revenue view to $99M-$101M from $98M-$100M

May 12, 2026, 4:30 PM EDT - 17 days ago

NeuroPace Earnings Call Transcript: Q1 2026

May 12, 2026, 4:30 PM EDT - 17 days ago

NeuroPace Earnings release: Q1 2026

May 12, 2026, 4:30 PM EDT - 17 days ago

NeuroPace Quarterly report: Q1 2026

May 12, 2026, 4:30 PM EDT - 17 days ago

NeuroPace Slides: Q1 2026

May 12, 2026, 4:05 PM EDT - 17 days ago

NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance

Apr 29, 2026, 4:05 PM EDT - 4 weeks ago

NeuroPace to Report First Quarter 2026 Financial Results on May 12, 2026

2026-04-27T11:45:05.000Z - 4 weeks ago

NeuroPace announces publication of 3-year results from RNS System PAS

Apr 27, 2026, 7:30 AM EDT - 4 weeks ago

NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

NeuroPace Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 5 weeks ago

NeuroPace Proxy statement: Proxy filing

Apr 14, 2026, 1:30 PM EDT - 6 weeks ago

NeuroPace Transcript: 25th Annual Needham Virtual Healthcare Conference

Apr 10, 2026, 4:05 PM EDT - 7 weeks ago

NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference

2026-03-18T10:25:19.000Z - 2 months ago

NeuroPace assumed with an Overweight at Wells Fargo

Mar 11, 2026, 8:40 AM EDT - 2 months ago

NeuroPace Transcript: Leerink Global Healthcare Conference 2026

Mar 5, 2026, 4:30 PM EST - 3 months ago

NeuroPace to Present at the Leerink Global Healthcare Conference

Mar 3, 2026, 4:30 PM EST - 3 months ago

NeuroPace Earnings Call Transcript: Q4 2025

Mar 3, 2026, 4:30 PM EST - 3 months ago

NeuroPace Earnings release: Q4 2025

Mar 3, 2026, 4:30 PM EST - 3 months ago

NeuroPace Annual report: Q4 2025

2026-03-03T21:20:04.000Z - 3 months ago

NeuroPace reports Q4 EPS (8c), consensus (17c)

2026-03-03T21:19:30.000Z - 3 months ago

NeuroPace sees Q1 revenue $21M-$22M, consensus $21.93M

2026-03-03T21:18:57.000Z - 3 months ago

NeuroPace sees FY26 revenue $98M-$100M, consensus $98.94M

Mar 3, 2026, 4:05 PM EST - 3 months ago

NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook

Mar 3, 2026, 4:00 PM EST - 3 months ago

NeuroPace Slides: Investor presentation

Feb 20, 2026, 4:30 PM EST - 3 months ago

NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026

2026-01-27T11:05:18.000Z - 4 months ago

NeuroPace price target raised to $19 from $18 at H.C. Wainwright

Jan 14, 2026, 6:00 PM EST - 4 months ago

NeuroPace Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 14, 2026, 6:00 PM EST - 4 months ago

NeuroPace Slides: 44th Annual J.P. Morgan Healthcare Conference

2026-01-13T12:41:09.000Z - 4 months ago

NeuroPace sees FY26 revenue $98M-$100M, consensus $98.44M

2026-01-13T12:40:52.000Z - 4 months ago

NeuroPace sees Q1 revenue $21M-$22M, consensus $22.35M

2026-01-13T12:35:40.000Z - 4 months ago

NeuroPace reports preliminary Q4 revenue $26.6M, consensus $24.43M

Jan 13, 2026, 7:30 AM EST - 4 months ago

NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook

Dec 31, 2025, 9:00 AM EST - 5 months ago

NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference

2025-12-17T13:25:23.000Z - 5 months ago

NeuroPace files premarket approval supplement application for RNS System

Dec 17, 2025, 8:00 AM EST - 5 months ago

NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy

2025-12-16T12:50:12.000Z - 5 months ago

NeuroPace price target raised to $22 from $18 at UBS

2025-12-10T12:25:21.000Z - 6 months ago

NeuroPace price target raised to $20 from $18 at JPMorgan

2025-12-08T13:16:09.000Z - 6 months ago

NeuroPace presents NAUTILUS trial data at American Epilepsy Society meeting

Dec 8, 2025, 8:00 AM EST - 6 months ago

NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy

Dec 2, 2025, 8:01 AM EST - 6 months ago

NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting

2025-11-24T13:16:08.000Z - 6 months ago

NeuroPace announces Medicare reimbursement increases for RNS System

Nov 24, 2025, 8:00 AM EST - 6 months ago

NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services

2025-11-05T12:31:11.000Z - 7 months ago

NeuroPace price target raised to $18 from $16 at JPMorgan

Nov 4, 2025, 4:30 PM EST - 7 months ago

NeuroPace Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

NeuroPace Quarterly report: Q3 2025

Nov 4, 2025, 4:30 PM EST - 7 months ago

NeuroPace Earnings release: Q3 2025

Nov 4, 2025, 4:05 PM EST - 7 months ago

NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Nov 4, 2025, 4:00 PM EST - 7 months ago

NeuroPace Slides: Investor Presentation

Oct 22, 2025, 8:00 AM EDT - 7 months ago

NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025

Sep 4, 2025, 9:45 AM EDT - 9 months ago

NeuroPace Transcript: Cantor Global Healthcare Conference 2025

Aug 28, 2025, 8:00 AM EDT - 9 months ago

NeuroPace to Participate in Upcoming Healthcare Conferences

Aug 13, 2025, 4:00 PM EDT - 10 months ago

NeuroPace Slides: Investor Presentation

Aug 12, 2025, 4:30 PM EDT - 10 months ago

NeuroPace Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

NeuroPace Quarterly report: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 10 months ago

NeuroPace Earnings release: Q2 2025

Aug 12, 2025, 4:05 PM EDT - 10 months ago

NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Aug 1, 2025, 7:30 AM EDT - 10 months ago

NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases

Jun 24, 2025, 4:05 PM EDT - 1 year ago

NeuroPace Announces Strategic CFO Transition

Jun 4, 2025, 4:09 PM EDT - 1 year ago

NeuroPace Secures Up to $75 Million in Debt Financing

May 27, 2025, 8:30 AM EDT - 1 year ago

NeuroPace Transcript: Status Update

May 27, 2025, 8:00 AM EDT - 1 year ago

NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study

focafoca99 May. 29 at 12:43 PM

$NPCE provides details on its participation at the ASSFN meeting, showcasing responsive neuromodulation and new RNS System data.

0 · Reply

Stock_Catcher May. 29 at 12:02 PM

$NPCE NeuroPace Announces FDA Approval of ECoG Assistant™, Advancing AI-Driven Epilepsy Care

0 · Reply

SuperGreenToday May. 19 at 1:16 PM

0 · Reply

MarketBeat May. 13 at 1:10 AM

https://marketbeat.com/a/8651185/ $NPCE NeuroPace Q1 Earnings Call Highlights

0 · Reply

EarningsInsider May. 12 at 10:16 PM

https://www.marketbeat.com/earnings/reports/2026-5-12-neuropace-inc-stock/ $NPCE NeuroPace Earnings Transcript

0 · Reply

StocktwitsEarnings May. 12 at 8:12 PM

0 · Reply

focafoca99 Apr. 11 at 9:03 PM

$NPCE management will present at the Needham Virtual Healthcare Conference on April 14.

0 · Reply

OfficialStocktwitsUser Mar. 23 at 3:54 PM

0 · Reply

StocktwitsEarnings Mar. 3 at 10:05 PM

0 · Reply

d_risk Mar. 3 at 10:03 PM

0 · Reply

BillionerOfKing Feb. 23 at 11:27 AM

$NPCE Current Stock Price: $14.35 Contracts to trade: $15.0 NPCE Mar 20 2026 Call Entry: $2.46 Exit: $3.25 ROI: 32% Hold ~29 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

Bogwood Feb. 22 at 10:50 PM

$NPCE $STAA Glad to see Patrick got quickly back on his feet after last year's implosion. I always felt like he and Tom were dealt short hands of the stick, just unlucky timing. What a consequential beard, though! 😂

0 · Reply

OfficialStocktwitsUser Feb. 21 at 1:34 PM

$NPCE RSI: 42.59, MACD: -0.4092 Vol: 0.68, MA20: 15.38, MA50: 15.95 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

VolatilityControl Feb. 18 at 4:40 PM

$NPCE NeuroPace develops implantable epilepsy devices. Adoption depends on physician acceptance and reimbursement. Growth is steady but niche.

0 · Reply

RebeccaDory286 Feb. 11 at 3:48 PM

$NPCE NeuroPace; medical device (responsive neurostimulation for epilepsy); commercial-stage; adoption is gradual, reimbursement path.

0 · Reply

topstockalerts Feb. 6 at 2:26 PM

$NPCE look who’s waking up..

0 · Reply

EquityEnforcer Feb. 4 at 4:07 PM

$NPCE is a medical device or healthcare services company; its performance would be tied to factors like patient volumes, reimbursement rates, or product adoption.

0 · Reply

IncognitoBull Jan. 30 at 1:24 PM

$NPCE if you believe in NPCE, you should also check out $NMTC competing tech, we are just getting to commercialization, but, our tech is targeting additional uses, brain, pain, and drug delivery. Ground floor prices vs a weighted top.

0 · Reply

OfficialStocktwitsUser Jan. 26 at 7:42 PM

$NPCE RSI: 54.51, MACD: 0.3089 Vol: 0.62, MA20: 16.40, MA50: 15.88 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Grubnednarb Jan. 8 at 3:47 AM

$NPCE

0 · Reply

Scoops1212 Jan. 7 at 6:05 PM

$NPCE This is about as frustrating of a stock that you can own. I’ve crunched all the numbers and this should be at 40+ right now there is something holding this price down, and it’s not visible in the numbers. Check their quarterly, and some big investors holding their position. When will this launch, as it’s long overdue?

0 · Reply

OfficialStocktwitsUser Dec. 29 at 11:20 AM

$NPCE RSI: 44.41, MACD: 0.5827 Vol: 0.38, MA20: 16.25, MA50: 13.84 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Market Cap	581.64M
Revenue (ttm)	99.99M
Net Income (ttm)	-21.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-21.47%
Debt to Equity Ratio	4.08

Volume	177,584
Avg Vol	194,812
Day's Range	N/A - N/A
Shares Out	34.09M
Stochastic %K	96%
Beta	1.92
Analysts	Strong Sell
Price Target	$20.00